Abbott Laboratories to Issue Earnings on October 21

The company projects third-quarter earnings per share between $1.38 and $1.46.

Updated on Oct. 21, 2026 in Economic Indicators

Bold flat-color editorial illustration in navy and cream showing a glass beaker with a rising stack of metallic plates, representing financial growth. — Abbott Laboratories is scheduled to release its third-quarter 2026 financial results on October 21, projecting adjusted earnings between $1.38 and $1.46 per share. AI Illustration. Upload story photo >

Live Poll

Do you believe major corporate earnings reports currently suggest the national economy is strengthening?

Abbott Laboratories is set to report its third-quarter financial results before U.S. markets open on October 21, 2026. The firm issued an adjusted earnings per share guidance range of $1.38 to $1.46 for the period.

Why it matters

The guidance provides investors with insight into Abbott's growth trajectory as it compares current expectations against the $1.30 per share recorded in the third quarter of 2025.

Abbott earned $1.30 per share on an adjusted basis and $11.37 billion in revenue in Q3 2025. In the second quarter of 2026, the firm reported $12.59 billion in sales and $1.31 in adjusted diluted earnings per share.

The players

Abbott Laboratories

Abbott Laboratories is a global medical devices and health care company.

The details

The upcoming report will be followed by a conference call at 9 a.m. ET to discuss the financial results. The company uses adjusted diluted earnings per share to measure performance against prior-year results.

Q3 2025 results were $1.30 in adjusted diluted EPS.
Q2 2026 results were $1.31 in adjusted diluted EPS.
Abbott reports third-quarter earnings on October 21, 2026.
The earnings call is scheduled for 9 a.m. ET on October 21, 2026.

Macro View

This earnings release follows the standardized disclosure patterns mandated for large-cap firms under the Securities and Exchange Commission's periodic financial reporting requirements. Current market performance mirrors broader cycles in the healthcare sector where firms provide adjusted EPS guidance to manage investor expectations.

The earnings report will provide investors and shareholders with updated metrics on the company's financial health and potential growth. These figures influence market valuations and the broader perception of the medical device and healthcare sector.

The takeaway

Investors should look for how the projected $1.38 to $1.46 per share guidance aligns with actual results during the October 21 call. This quarterly cycle serves as a critical benchmark for evaluating the firm's operational efficiency and market position.

What happens next

Abbott Laboratories will release its third-quarter earnings report on October 21, 2026, followed by a scheduled conference call at 9 a.m. ET that same day.